ArticleAmerican journal of translational research2023
Efficacy of hemodialysis combined with hemofiltration in the treatment of uremia complicated with intractable hypertension.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Study on the occurrence and influencing factors of gastrointestinal symptoms in hemodialysis patients with uremia.World journal of gastrointestinal surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the efficacy of hemodialysis and hemofiltration in the management of uremia complicated with refractory hypertension (RH).
methodsIn this retrospective study, 80 patients with uremia complicated with RH who were admitted to the First People's Hospital of Huoqiu County from March 2019 to March 2022 were included. Patients who received routine hemodialysis were assigned to the control group (C group, n=40), whereas patients received routine hemodialysis and hemofiltration were assigned to the observational group (R group, n=40). The clinical indexes of the two groups were recorded and compared. Differences in diastolic blood pressure, systolic blood pressure, mean pulsating blood pressure, urinary protein, blood urea nitrogen (BUN) and urinary microalbumin, cardiac function parameters and plasma toxic metabolites were observed after one month of treatment.
resultsThe effective rate of the treatment in the observation group was 97.50%, whereas that for the control group was 75.00%. The observation group showed significantly better improvement of diastolic blood pressure, systolic blood pressure and mean arterial pressure compared with the control group (all P<0.05). The levels of urinary microalbumin were lower after treatment than those before treatment. The levels of urinary protein and BUN were higher in the observation group than those in the control group; and the levels of urinary microalbumin were significantly lower in the observation group compared with the levels in the control group (all P<0.05). The cardiac parameters of the study cohort were significantly lower after treatment. The levels of plasma toxic metabolites in the observation group were significantly lower after the 12-week treatment.
conclusionHemodialysis combined with hemofiltration is effective in the management of uremic patients with refractory hypertension. This treatment strategy effectively reduces blood pressure and average pulsation, improves cardiac function, and promotes the clearance of toxic metabolites. The method is associated with fewer adverse reactions and is safe for clinical applications.
Indexed as
Identifiers
37303622PMC10250981W4380290854What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.